Stock BVNRY BAVARIAN NORDIC A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bavarian Nordic A/S OTC Markets

Equities

BVNRY

US0717711099

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 15:56:03 2024-05-31 EDT 		5-day change 1st Jan Change
8.93 USD +4.66% Intraday chart for Bavarian Nordic A/S +3.18% +2.12%
05-31 Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine MT
05-30 Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,541 10,910 18,904 15,064 13,830 14,387 - -
Enterprise Value (EV) 1 6,840 9,710 16,160 13,341 11,979 14,410 13,538 11,879
P/E ratio -16 x 36.7 x -36.3 x -43.6 x 9.24 x 20.7 x 15.3 x 15.5 x
Yield - - - - - - - -
Capitalization / Revenue 8.36 x 5.89 x 9.96 x 4.78 x 1.96 x 2.75 x 2.85 x 2.77 x
EV / Revenue 10.3 x 5.24 x 8.51 x 4.23 x 1.7 x 2.76 x 2.68 x 2.28 x
EV / EBITDA -25.2 x 13.1 x 216 x 40.7 x 4.58 x 10.9 x 8.51 x 7.18 x
EV / FCF -10.8 x 26.5 x -19.2 x -94.5 x 12.3 x -382 x 8.06 x 6.84 x
FCF Yield -9.3% 3.78% -5.21% -1.06% 8.15% -0.26% 12.4% 14.6%
Price to Book 2.97 x 2.23 x 2.57 x 2.1 x 1.34 x 1.28 x 1.23 x 1.12 x
Nbr of stocks (in thousands) 32,321 58,342 70,329 70,589 77,937 77,828 - -
Reference price 2 171.4 187.0 268.8 213.4 177.4 184.8 184.8 184.8
Announcement Date 2/20/20 3/12/21 3/4/22 3/2/23 3/6/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 662.5 1,852 1,898 3,151 7,062 5,230 5,051 5,202
EBITDA 1 -271.4 739.8 74.8 328 2,615 1,318 1,591 1,654
EBIT 1 -328.4 395.7 -312.9 -70.78 2,060 847 1,083 1,188
Operating Margin -49.57% 21.36% -16.49% -2.25% 29.17% 16.19% 21.43% 22.85%
Earnings before Tax (EBT) 1 -344.7 282 -454.4 -331.6 1,483 827.5 1,089 1,185
Net income 1 -346.8 277.5 -464.8 -347.4 1,475 689 947.3 923
Net margin -52.35% 14.98% -24.49% -11.03% 20.89% 13.17% 18.76% 17.74%
EPS 2 -10.70 5.100 -7.400 -4.900 19.20 8.920 12.11 11.92
Free Cash Flow 1 -636 367.1 -841.6 -141.2 976.7 -37.72 1,680 1,736
FCF margin -96% 19.82% -44.35% -4.48% 13.83% -0.72% 33.25% 33.38%
FCF Conversion (EBITDA) - 49.62% - - 37.36% - 105.59% 104.96%
FCF Conversion (Net income) - 132.27% - - 66.21% - 177.29% 188.14%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/20/20 3/12/21 3/4/22 3/2/23 3/6/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 544 320 537 1,004 1,290 1,252 1,987 1,376 2,447 831.5 1,100 1,400 1,810
EBITDA 1 31.2 -94 -118 226 313.6 481.5 689.7 380 1,063 21.84 150 300 965
EBIT 1 -71.31 -192.1 -217.6 128 211 369.8 546.2 231.6 912.6 - 150 300 518
Operating Margin -13.11% -60.03% -40.53% 12.75% 16.35% 29.53% 27.49% 16.83% 37.29% - 13.64% 21.43% 28.62%
Earnings before Tax (EBT) -97.75 -270.6 -235.9 19.34 155.5 376.5 542.7 -334.5 898.2 -114.1 - - -
Net income 1 -102.2 -271.9 -237.2 12.11 149.6 376.4 538.1 -340.6 901.3 -114.5 150 300 364
Net margin -18.79% -84.98% -44.17% 1.21% 11.59% 30.06% 27.09% -24.76% 36.83% -13.76% 13.64% 21.43% 20.11%
EPS 2 -1.600 -3.900 -3.400 0.2000 2.200 5.100 7.100 -4.400 11.70 -1.500 7.520 15.00 18.20
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/4/22 5/9/22 8/24/22 11/9/22 3/2/23 5/9/23 8/23/23 11/16/23 3/6/24 5/8/24 - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,298 - - - - 23.7 - -
Net Cash position 1 - 1,200 2,745 1,723 1,850 - 849 2,507
Leverage (Debt/EBITDA) -4.783 x - - - - 0.018 x - -
Free Cash Flow 1 -636 367 -842 -141 977 -37.7 1,680 1,737
ROE (net income / shareholders' equity) -17.1% 8.21% -7.58% -4.78% 16.9% 6.45% 7.96% 7.45%
ROA (Net income/ Total Assets) -6.86% 3.51% - -2.84% 11% 4.8% 5.66% 6.19%
Assets 1 5,054 7,903 - 12,240 13,371 14,342 16,749 14,909
Book Value Per Share 2 57.70 83.70 105.0 102.0 132.0 144.0 151.0 166.0
Cash Flow per Share 2 -8.550 10.60 -5.680 3.120 14.60 2.900 18.80 25.00
Capex 1 360 205 483 361 143 300 278 190
Capex / Sales 54.36% 11.06% 25.46% 11.47% 2.02% 5.74% 5.5% 3.65%
Announcement Date 2/20/20 3/12/21 3/4/22 3/2/23 3/6/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bavarian Nordic A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
184.8 DKK
Average target price
262 DKK
Spread / Average Target
+41.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BAVA Stock
  4. BVNRY Stock
  5. Financials Bavarian Nordic A/S